Elaine Mardis, co-director of the Genome Institute at Washington University in St. Louis, discussed genomic testing for cancer in both clinical research and diagnosis.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
An international team of researchers has sequenced the wheat pathogen Mayetiola destructor to find a large repertoire of effector genes that may help it infect plants.
This online seminar describes new technology capable of generating mate-pair sequencing reads up to 50 kb in length, enabling de novo genome assembly, closure, and finishing on the Illumina or Ion Torrent next-generation sequencing platforms.
As the molecular profiling Caris Life Sciences performs for cancer patients has advanced, the company's needs for managing high-performance analytics and storage have grown exponentially. Its next-generation sequencing (NGS) processes are now fully supported by IBM supercomputing technologies, including processing by IBM NeXtScale System servers.
Hadoop MapReduce is fast becoming a core technology in the exciting fast moving field of genome research. This whitepaper explains how IBM Platform Symphony helps dramatically accelerate Contrail, an important toolset in de novo genome assembly.
